For this reason, we first measured 3H-thymidine uptake to assess the dose-dependent effect of X-396 and crizotinib on the growth of two NB cell lines, each one harbouring one of the hot spot-activating ALK-mutations: LAN-5 carrying R1275Q ALK mutation (ALKR1275Q) and SH-SY5Y carrying F1174L ALK mutation (ALKF1174L). The gene discussed is ALK; the disease is neuroblastoma.